Clinical trial
A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled, Parallel-group, Group-sequential Study to Investigate Safety and Effectiveness of the Rehaler Partial Rebreathing Device, in Adults Suffering From Migraine With Aura
NCT05546385 is registered in ClinicalTrials.gov with Rehaler as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled, Parallel-group, Group-sequential Study to Investigate Safety and Effectiveness of the Rehaler Partial Rebreathing Device, in Adults Suffering From Migraine With Aura
- Lead sponsor
- Rehaler
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- August 8, 2023
- Completion date
- October 30, 2024
- Enrollment
- 142 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.